188 related articles for article (PubMed ID: 32412942)
1. Developing a New Version of the SF-6D Health State Classification System From the SF-36v2: SF-6Dv2.
Brazier JE; Mulhern BJ; Bjorner JB; Gandek B; Rowen D; Alonso J; Vilagut G; Ware JE;
Med Care; 2020 Jun; 58(6):557-565. PubMed ID: 32412942
[TBL] [Abstract][Full Text] [Related]
2. Valuing the SF-6Dv2 Classification System in the United Kingdom Using a Discrete-choice Experiment With Duration.
Mulhern BJ; Bansback N; Norman R; Brazier J;
Med Care; 2020 Jun; 58(6):566-573. PubMed ID: 32221100
[TBL] [Abstract][Full Text] [Related]
3. Consistency Between Three Different Ways of Administering the Short Form 6 Dimension Version 2.
Poder TG; Fauteux V; He J; Brazier JE
Value Health; 2019 Jul; 22(7):837-842. PubMed ID: 31277832
[TBL] [Abstract][Full Text] [Related]
4. A Comparison of the SF-6Dv2 and SF-6D UK Utility Values in a Mixed Patient and Healthy Population.
McDool E; Mukuria C; Brazier J
Pharmacoeconomics; 2021 Aug; 39(8):929-940. PubMed ID: 34043147
[TBL] [Abstract][Full Text] [Related]
5. Valuing the SF-6Dv2 in the capital of Iran using a discrete choice experiment with duration.
Daroudi R; Zeraati H; Poder TG; Norman R; Olyaeemanesh A; Sari AA; Ameri H
Qual Life Res; 2024 Jul; 33(7):1853-1863. PubMed ID: 38630166
[TBL] [Abstract][Full Text] [Related]
6. The development of a model for translation of the Neck Disability Index to utility scores for cost-utility analysis in cervical disorders.
Richardson SS; Berven S
Spine J; 2012 Jan; 12(1):55-62. PubMed ID: 22209244
[TBL] [Abstract][Full Text] [Related]
7. Unchained melody: revisiting the estimation of SF-6D values.
Craig BM
Eur J Health Econ; 2016 Sep; 17(7):865-73. PubMed ID: 26359242
[TBL] [Abstract][Full Text] [Related]
8. Psychometric properties of the SF-6Dv2 in an Iranian breast cancer population.
Nahvijou A; Safari H; Ameri H
Breast Cancer; 2021 Jul; 28(4):937-943. PubMed ID: 33666840
[TBL] [Abstract][Full Text] [Related]
9. Using the Multiple Sclerosis Impact Scale to estimate health state utility values: mapping from the MSIS-29, version 2, to the EQ-5D and the SF-6D.
Hawton A; Green C; Telford C; Zajicek J; Wright D
Value Health; 2012 Dec; 15(8):1084-91. PubMed ID: 23244811
[TBL] [Abstract][Full Text] [Related]
10. Cancer population norms using a new value set for the SF-6Dv2 based on the preferences of patients with breast or colorectal cancer in Quebec.
Touré M; Sfairy SM; Bédard SK; McFadden N; Hanel R; Lemay F; He J; Pavic M; Poder TG
Qual Life Res; 2024 Jun; 33(6):1605-1619. PubMed ID: 38642218
[TBL] [Abstract][Full Text] [Related]
11. Valuing SF-6Dv2 in Australia Using an International Protocol.
Mulhern B; Norman R; Brazier J
Pharmacoeconomics; 2021 Oct; 39(10):1151-1162. PubMed ID: 34250578
[TBL] [Abstract][Full Text] [Related]
12. EQ-5D-5L and SF-6D Utility Measures in Symptomatic benign Thyroid Nodules: Acceptability and Psychometric Evaluation.
Wong CKH; Lang BHH; Yu HMS; Lam CLK
Patient; 2017 Aug; 10(4):447-454. PubMed ID: 28224296
[TBL] [Abstract][Full Text] [Related]
13. Valuing SF-6D Health States Using a Discrete Choice Experiment.
Norman R; Viney R; Brazier J; Burgess L; Cronin P; King M; Ratcliffe J; Street D
Med Decis Making; 2014 Aug; 34(6):773-86. PubMed ID: 24025661
[TBL] [Abstract][Full Text] [Related]
14. Development of the SF-6Dv2 health utility survey: comprehensibility and patient preference.
Broderick L; Bjorner JB; Lauher-Charest M; White MK; Kosinski M; Mulhern B; Brazier J
J Patient Rep Outcomes; 2022 May; 6(1):47. PubMed ID: 35551545
[TBL] [Abstract][Full Text] [Related]
15. The Simplified Chinese version of SF-6Dv2: translation, cross-cultural adaptation and preliminary psychometric testing.
Wu J; Xie S; He X; Chen G; Brazier JE
Qual Life Res; 2020 May; 29(5):1385-1391. PubMed ID: 31950328
[TBL] [Abstract][Full Text] [Related]
16. SF-6D population norms for the Hong Kong Chinese general population.
Wong CKH; Mulhern B; Cheng GHL; Lam CLK
Qual Life Res; 2018 Sep; 27(9):2349-2359. PubMed ID: 29797176
[TBL] [Abstract][Full Text] [Related]
17. Differential Psychometric Properties of EuroQoL 5-Dimension 5-Level and Short-Form 6-Dimension Utility Measures in Low Back Pain.
Cheung PWH; Wong CKH; Cheung JPY
Spine (Phila Pa 1976); 2019 Jun; 44(11):E679-E686. PubMed ID: 30475342
[TBL] [Abstract][Full Text] [Related]
18. SF-6Dv2 preference value set for health utility in food allergy.
Dufresne É; Poder TG; Samaan K; Lacombe-Barrios J; Paradis L; Des Roches A; Bégin P
Allergy; 2021 Jan; 76(1):326-338. PubMed ID: 32533705
[TBL] [Abstract][Full Text] [Related]
19. Comparing the Performance of 2 Health Utility Measures in the Medicare Health Outcome Survey (HOS).
Jia H; Lubetkin EI; DeMichele K; Stark DS; Zack MM; Thompson WW
Med Decis Making; 2018 Nov; 38(8):983-993. PubMed ID: 30403580
[TBL] [Abstract][Full Text] [Related]
20. Developing and testing methods for deriving preference-based measures of health from condition-specific measures (and other patient-based measures of outcome).
Brazier JE; Rowen D; Mavranezouli I; Tsuchiya A; Young T; Yang Y; Barkham M; Ibbotson R
Health Technol Assess; 2012 Jul; 16(32):1-114. PubMed ID: 22832015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
